Tarsus Pharmaceuticals (TARS) EBITDA (2019 - 2026)

Tarsus Pharmaceuticals' EBITDA history runs 8 years deep, the most recent figure standing at -$6.1 million for Q1 2026.

• In Q1 2026, EBITDA rose 76.7% year-over-year to -$6.1 million; the TTM figure through Mar 2026 stood at -$50.8 million (up 53.45% YoY), while the FY2025 annual figure was -$71.0 million, up 41.14% from the prior year.
• EBITDA for Q1 2026 stood at -$6.1 million, up from -$8.0 million in the prior quarter.
• The five-year high for EBITDA was -$5.2 million in Q2 2022, with the low at -$44.4 million in Q4 2023.
• The 5-year median for EBITDA is -$24.4 million (2024), against an average of -$23.7 million.
• The sharpest annual moves came in 2023 and 2026: EBITDA slumped 528.27% in 2023, then soared 76.7% in 2026.
• Tarsus Pharmaceuticals' EBITDA stood at -$15.1 million in 2022, then sank by 195.13% to -$44.4 million in 2023, then jumped by 45.06% to -$24.4 million in 2024, then surged by 67.34% to -$8.0 million in 2025, then rose by 23.24% to -$6.1 million in 2026.
• Business Quant data shows TARS's EBITDA at -$6.1 million in Q1 2026, -$8.0 million in Q4 2025, and -$14.5 million in Q3 2025.